Opinions
Rob Lauzon
Intellia Therapeutics
NTLA-Q
TOP PICK
Mar 25, 2024
$26.810
Stock price when the opinion was issued
biotechnology
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
RISKY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research
NTLA has $912.2M in total cash and short term investments. Cash and equivalents is $226.7M while $685.5M is in short term investments. Insider ownership is 9.39%. NTLA is expected to be highly unprofitable over the next three years, but revenue is expected grow at 40% this year, then flat in 2025. We think it is a very speculative play and it is also highly unprofitable and burning through cash at a high rate. Share price appreciation will be reliant on bringing NTLA-2001 to market.
Unlock Premium - Try 5i Free
biotechnology
Advertising
Biotech is an exciting area to be looking at. It is higher growth but higher risk - along with higher reward. Biotech has under-performed for the past two years. Intellia has used crisper technology to target mutated genes dealing with autoimmune and rare diseases - and try to cure them. They are at third stage trials this year. It has $2 billion cash which is good for two years of R&D. Management is good. Buy 25 Hold 6 Sell 0
(Analysts’ price target is $69.96)